Objective: Antidepressants, in particular Atomextine, along with stimulants have demonstrated benefit in the treatment of ADHD. Agomelatine is a new antidepressant with additional affinities to the melatonergic system. As ADHD has been associated with sleep disorders, it is assumed that Agomelatiine might serve as a therapeutic alternative to treat patients with the ADHD refractory to first line medications. Method: Ten late adolescents were evaluated in a placebo controlled manner. Results: Agomelatine's effect was superior to that of placebo but appeared to be less than that of first line medications such as methylphenidate. Conclusion: Agomelatine may be a useful second line medication for individuals with ADHD, particularly if they suffer from additional sleep disorders. (Contains 1 table.)